Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Sep 17.
doi: 10.1111/apt.70340. Online ahead of print.

Editorial: Managing the Moving Target-Dose Adjustments in Inflammatory Bowel Disease

Nicholas Clark  1 , Daniel Tassone  1 , Nik Sheng Ding  1
Affiliations
Editorial

Editorial: Managing the Moving Target-Dose Adjustments in Inflammatory Bowel Disease

Nicholas Clark et al. Aliment Pharmacol Ther. .
No abstract available

PubMed Disclaimer

References

    1. A. S. Strik, M. Löwenberg, and C. J. Buskens, “B Gecse K, I Ponsioen C, Bemelman WA, D'haens GR. Higher Anti‐TNF Serum Levels Are Associated With Perianal Fistula Closure in Crohn's Disease Patients,” Scandinavian Journal of Gastroenterology 54, no. 4 (2019): 453–458, https://doi.org/10.1080/00365521.2019.1600014.
    1. J. D. Schulberg, E. K. Wright, B. A. Holt, et al., “Intensive Drug Therapy Versus Standard Drug Therapy for Symptomatic Intestinal Crohn's Disease Strictures (STRIDENT): An Open‐Label, Single‐Centre, Randomised Controlled Trial,” Lancet Gastroenterology & Hepatology 7, no. 4 (2022): 318–331, https://doi.org/10.1016/S2468‐1253(21)00393‐9.
    1. C. de Rubín Célix, E. Ricart, M. D. Martín‐Arranz, et al., “Frequency and Effectiveness of Dose Escalation and De‐Escalation of Biologic Therapy in Inflammatory Bowel Disease: The RAINBOW‐IBD Study of ENEIDA,” Alimentary Pharmacology & Therapeutics (2025): 1–16, https://doi.org/10.1111/apt.70312.

Publication types

LinkOut - more resources